Michael Heuser

发表

Method and apparatus for producing a component with an integrated insert

Christoph Pille, Hermann Pleteit, Michael Heuser, 2009 .

Method and device for manufacturing a component with an insert integrated

Christoph Pille, Hermann Pleteit, Michael Heuser, 2009 .

EP-1428: Functional requirements in public tendering for linear accelerators and ROKIS

Michael Heuser, Gerd Lutters, S. Khan, 2014 .

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Michael Heuser, Katharina Wagner, Brigitte Schlegelberger, 2010, Blood.

Precision oncology for acute myeloid leukemia using a knowledge bank approach

Inigo Martincorena, Verena I Gaidzik, Peter J Campbell, 2017, Nature Genetics.

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

Ulrich Lehmann, Ute Modlich, Michael Heuser, 2013, Blood.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Torsten Haferlach, Claude Preudhomme, Wolfgang Kern, 2018, Blood.

Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.

Michael Heuser, Lars Bullinger, Brigitte Schlegelberger, 2005, Haematologica.

Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.

Franco Locatelli, Michael Heuser, Seishi Ogawa, 2012, Blood.

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Verena I Gaidzik, Michael Heuser, Lars Bullinger, 2019, Nature Communications.

In-depth characterization of the microRNA transcriptome in a leukemia progression model.

Malachi Griffith, Thomas Zeng, Ryan D. Morin, 2008, Genome research.

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.

Michael Heuser, Brigitte Schlegelberger, Arnold Ganser, 2012, Blood.

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

Michael Heuser, Katharina Wagner, Brigitte Schlegelberger, 2010, Haematologica.

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Benjamin L. Ebert, Michael R. Savona, John M. Bennett, 2019, Nature Medicine.

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

Michael Heuser, Daniela Weber, Hartmut Döhner, 2015, British journal of haematology.

Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group.

Verena I Gaidzik, Thomas Schroeder, Thomas Kindler, 2019, Blood.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Michael Stadler, Verena I Gaidzik, Michael Heuser, 2018, Blood.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Arnaud Pigneux, Gary Acton, Michael Heuser, 2015, The Lancet. Oncology.